Positive modulation of cognition and mood in the healthy elderly volunteer following administration of Centella asiatica
Department of Physiology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand. Journal of Ethnopharmacology
(Impact Factor: 3).
04/2008; 116(2):325-32. DOI: 10.1016/j.jep.2007.11.038
AIMS OF THIS STUDY: Centella asiatica has a reputation to restore decline cognitive function in traditional medicine and in animal model. However, little evidence regarding the efficacy of Centella asiatica from systematized trials is available. Therefore, the present randomized, placebo-controlled, double-blind study investigated the effect of Centella asiatica on cognitive function of healthy elderly volunteer.
Twenty-eight healthy elderly participants received the plant extract at various doses ranging 250, 500 and 750 mg once daily for 2 months. Cognitive performance was assessed using the computerized test battery and event-related potential whereas mood was assessed using Bond-Lader visual analogue scales prior to the trial and after single, 1 and 2 months after treatment.
The results showed that the high dose of the plant extract enhanced working memory and increased N100 component amplitude of event-related potential. Improvements of self-rated mood were also found following the Centella asiatica treatment.
Therefore, the present findings suggest the potential of Centella asiatica to attenuate the age-related decline in cognitive function and mood disorder in the healthy elderly. However, the precise mechanism(s) underlying these effects still require further investigation.
Available from: Nora E Gray
- "An extract of Centella asiatica was also shown to decrease A␤ plaque burden in a transgenic mouse model of AD, however the extraction method was not described, making it difficult to speculate which compounds may be responsible for that effect . In addition to these effects, the cognitive enhancing action of water extracts of Centella asiatica has also been demonstrated in multiple animal models    and in limited human studies    . "
[Show abstract] [Hide abstract]
ABSTRACT: The accumulation of amyloid-β (Aβ) is a hallmark of Alzheimer's disease and is known to result in neurotoxicity both in vivo and in vitro. We previously demonstrated that treatment with the water extract of Centella asiatica (CAW) improves learning and memory deficits in Tg2576 mice, an animal model of Aβ accumulation. However the active compounds in CAW remain unknown. Here we used two in vitro models of Aβ toxicity to confirm this neuroprotective effect and identify several active constituents of the CAW extract. CAW reduced Aβ-induced cell death and attenuated Aβ-induced changes in tau expression and phosphorylation in both the MC65 and SH-SY5Y neuroblastoma cell lines. We confirmed and quantified the presence of several mono- and dicaffeoylquinic acids (CQAs) in CAW using chromatographic separation coupled to mass spectrometry and ultraviolet spectroscopy. Multiple dicaffeoylquinic acids showed efficacy in protecting MC65 cells against Aβ-induced cytotoxicity. Isochlorogenic acid A and 1,5-dicaffeoylquinic acid were found to be the most abundant CQAs in CAW, and the most active in protecting MC65 cells from Aβ-induced cell death. Both compounds showed neuroprotective activity in MC65 and SH-SY5Y cells at concentrations comparable to their levels in CAW. Each compound not only mitigated Aβ-induced cell death, but was able to attenuate Aβ-induced alterations in tau expression and phosphorylation in both cell lines, as seen with CAW. These data suggest that CQAs are active neuroprotective components in CAW, and therefore are important markers for future studies on CAW standardization, bioavailability, and dosing.
Journal of Alzheimer's disease: JAD 01/2014; 40(2). DOI:10.3233/JAD-131913 · 4.15 Impact Factor
Available from: PubMed Central
- "Early clinical evidence suggests improvement in cognitive function associated with Centella asiatica . More recently, an aqueous extract of Centella asiatica standardized to constituent tannic acids, as well as asiaticoside and asiatic acid, improved cognitive performance in healthy men and women [43, 44] and in elderly subjects with mild cognitive impairment [45, 46]. "
[Show abstract] [Hide abstract]
ABSTRACT: Background. SuperUlam is a proprietary blend of natural ingredients aimed at supporting brain health. We aimed to evaluate the effect of SuperUlam on attention and mood in healthy adults. Methods. Twenty healthy individuals aged 35-65 were enrolled in this randomized, double-blind, placebo-controlled, crossover study. Study duration was 3 weeks and consisted of 3 visits. Measurement of cognitive function included computer-based testing of reaction time, complex attention, working memory, sustained attention, and executive functioning. Mood testing was performed via the profile of mood states (POMS) survey and the Chalder fatigue scale. Results. Cognitive function testing demonstrated a significant improvement from baseline in executive functioning, cognitive flexibility, reaction time, and working memory in the product group only (P < 0.05). When comparing the study product to placebo, the data demonstrated a significant decrease in tension, depression, and anger (P < 0.05). There was no significant difference between the product and placebo in the other measures of mood, including vigor, fatigue, confusion, and total mood disturbance. No adverse events were reported. Conclusions. Supplementation with SuperUlam is safe to consume with potential benefits to cognitive function and mood.
Evidence-based Complementary and Alternative Medicine 11/2013; 2013(2):238454. DOI:10.1155/2013/238454 · 1.88 Impact Factor
Available from: Mayuree H. Tantisira
- "Based on well-defined constituents and numbers of scientific evidence, EGb 761, a standardized extract of Chinese ancient plant, Ginko biloba, known as a brain tonic remedy, has been prescribed for memory deficit all over the world . By the same analogy, C. asiatica which has long been used in Ayurveda to enhance memory was extensively investigated . In an attempt to make a reliable herbal product, ECa 233, a standardized extract of C. asiatica, was established and investigated for its effect on brain function. "
[Show abstract] [Hide abstract]
ABSTRACT: In order to gain insight into neuroprotective effects of ECa 233, a standardized extract of Centella asiatica, previously demonstrated in animal models of memory impairment induced by transient global ischemia or intracerebroventricular injection of beta-amyloid, the effect of ECa 233 on neurite outgrowth of human IMR-32 neuroblastoma cell line was investigated.
Cells were seeded and incubated with various concentrations of ECa 233. Morphometric analysis was carried out by a measurement of the longest neurite growth of cells at 24 and 48 h. Contributing signaling pathways possibly involved were subsequently elucidated by western blot analysis.
While ECa 233 had only limited effects on cell viability, it significantly enhanced neurite outgrowth of IMR-32 cells at the concentrations of 1--100 mug/ml. Western blot analysis revealed that ECa 233 significantly upregulated the level of activated ERK1/2 and Akt of the treated cells suggesting their involvement in the neuritogenic effect observed, which was subsequently verified by the finding that an addition of their respective inhibitors could reverse the effect of ECa 233 on these cells.
The present study clearly demonstrated neurite outgrowth promoting activity of ECa 233. ERK1/2 and Akt signaling pathways seemed to account for the neurotrophic effect observed. In conjunction with in vivo neuroprotective effect of ECa 233 previously reported, the results obtained support further development of ECa 233 for clinical use in neuronal injury or neurodegenerative diseases.
BMC Complementary and Alternative Medicine 08/2013; 13(1):204. DOI:10.1186/1472-6882-13-204 · 2.02 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.